134 related articles for article (PubMed ID: 37389814)
21. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.
Andrews JR; Ahmed ME; Sharma V; Britton C; Stish B; Phillips R; Kendi AT; Joshi VB; Sood A; Tollefson MK; Boorjian SA; Karnes RJ; Kwon ED
J Urol; 2022 Dec; 208(6):1240-1249. PubMed ID: 36349914
[TBL] [Abstract][Full Text] [Related]
22. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
de Vries KC; Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):108-115. PubMed ID: 31593756
[TBL] [Abstract][Full Text] [Related]
23. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
24. Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Aug; 21(4):783-790. PubMed ID: 26843024
[TBL] [Abstract][Full Text] [Related]
25. A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.
Yamaguchi Y; Hayashi Y; Ishizuya Y; Takeda K; Nakai Y; Arai Y; Nakayama M; Kakimoto K; Nishimura K
Jpn J Clin Oncol; 2015 Feb; 45(2):197-201. PubMed ID: 25381383
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
[TBL] [Abstract][Full Text] [Related]
27. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
[TBL] [Abstract][Full Text] [Related]
28. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
[TBL] [Abstract][Full Text] [Related]
29. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.
Park S; Meng MV; Elkin EP; Speight JL; DuChane J; Carroll PR
J Urol; 2005 Nov; 174(5):1802-7. PubMed ID: 16217291
[TBL] [Abstract][Full Text] [Related]
30. Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.
Wang EC; Lee WR; Armstrong AJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):30-40. PubMed ID: 36203051
[TBL] [Abstract][Full Text] [Related]
31. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
32. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
33. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.
Bryant AK; McKay RR; Kader AK; Parsons JK; Einck JP; Kane CJ; Mundt AJ; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1068-1076. PubMed ID: 30543857
[TBL] [Abstract][Full Text] [Related]
34. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
Yang DD; Mahal BA; Muralidhar V; Boldbaatar N; Labe SA; Nezolosky MD; Vastola ME; Beard CJ; Martin NE; Mouw KW; Orio PF; King MT; Nguyen PL
Cancer; 2017 Dec; 123(24):4832-4840. PubMed ID: 28832984
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
36. Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance.
Whalen MJ; Pak JS; Lascano D; Ahlborn D; Matulay JT; McKiernan JM; Benson MC; Wenske S
Clin Genitourin Cancer; 2018 Apr; 16(2):e425-e435. PubMed ID: 29113772
[TBL] [Abstract][Full Text] [Related]
37. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
38. Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function.
Joyce DD; Wallis CJD; Luckenbaugh AN; Huelster HL; Zhao Z; Hoffman KE; Huang LC; Koyama T; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; Neil BBO; Kaplan SH; Greenfield S; Penson DF; Barocas DA
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):238-247. PubMed ID: 34108648
[TBL] [Abstract][Full Text] [Related]
39. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy.
Patel SA; Goyal S; Liu Y; Moghanaki D; Patel PR; Hanasoge S; Dhere VR; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck BW
JAMA Netw Open; 2020 Dec; 3(12):e2025143. PubMed ID: 33301015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
